Literature DB >> 7066169

The addition of prazosin to standard triple therapy in the treatment of severe hypertension.

A M Heagerty, G I Russell, R F Bing, H Thurston, J D Swales.   

Abstract

1 A small dose of prazosin was added to the treatment regime of sixteen hypertensive patients poorly controlled on a combination of bendrofluazide, hydralazine and propranolol. 2 There was a significant improvement in blood pressure control in all patients at 1 month (P less than 0.01) and this was maintained at 9 months (P less than 0.02). Tolerance to prazosin was not a problem. 3 The addition of prazosin to conventional triple drug therapy produces a further useful fall in blood pressure.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7066169      PMCID: PMC1402042          DOI: 10.1111/j.1365-2125.1982.tb01418.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Partial versus complete control of blood pressure in the prevention of hypertensive complications.

Authors:  J Taguchi; E D Freis
Journal:  Circ Res       Date:  1975-06       Impact factor: 17.367

2.  Effects of prazosin on forearm resistance and capacitance vessels.

Authors:  N A Awan; R R Miller; K Maxwell; D T Mason
Journal:  Clin Pharmacol Ther       Date:  1977-07       Impact factor: 6.875

Review 3.  Captopril in the treatment of clinical hypertension and cardiac failure.

Authors:  A B Atkinson; J I Robertson
Journal:  Lancet       Date:  1979-10-20       Impact factor: 79.321

4.  Studies with prazosin--a new effective hypotensive agent. II. Two double-blind cross-over studies comparing the effects of prazosin and hydrallazine.

Authors:  A S Hua; I M Macdonald; J B Myers; P Fang; P Kincaid-Smith
Journal:  Med J Aust       Date:  1977-07-02       Impact factor: 7.738

5.  Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. A cooperative study.

Authors: 
Journal:  JAMA       Date:  1977-01-17       Impact factor: 56.272

6.  Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure.

Authors:  M Packer; J Meller; R Gorlin; M V Herman
Journal:  Circulation       Date:  1979-03       Impact factor: 29.690

7.  Prazosin: the first-dose phenomenon.

Authors:  R M Graham; I R Thornell; J M Gain; C Bagnoli; H F Oates; G S Stokes
Journal:  Br Med J       Date:  1976-11-27

8.  Hydrallazine in hypertension: is there a safe dose?

Authors:  R F Bing; G I Russell; H Thurston; J D Swales
Journal:  Br Med J       Date:  1980-08-02

Review 9.  Minoxidil and the treatment of severe hypertension.

Authors:  W A Pettinger
Journal:  N Engl J Med       Date:  1980-10-16       Impact factor: 91.245

10.  Evaluation of beta blockade bendrofluazide, and prazosin in severe hypertension.

Authors:  A J Marshall; D W Barritt; J Pocock; S T Heaton
Journal:  Lancet       Date:  1977-02-05       Impact factor: 79.321

  10 in total
  3 in total

1.  The pharmacological basis for the use of alpha 1-adrenoceptor antagonists in the treatment of essential hypertension.

Authors:  M J Davey
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

Review 2.  Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure.

Authors:  W F Stanaszek; D Kellerman; R N Brogden; J A Romankiewicz
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546

3.  Induction of Tet3-dependent Epigenetic Remodeling by Low-dose Hydralazine Attenuates Progression of Chronic Kidney Disease.

Authors:  Björn Tampe; Desiree Tampe; Elisabeth M Zeisberg; Gerhard A Müller; Wibke Bechtel-Walz; Michael Koziolek; Raghu Kalluri; Michael Zeisberg
Journal:  EBioMedicine       Date:  2015-01       Impact factor: 8.143

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.